查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978255

2026-2034年全球腫瘤伴隨診斷測試市場規模、佔有率、趨勢和成長分析報告

Global Companion Diagnostic Tests in Oncology Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 169 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計腫瘤伴隨診斷測試的市場規模將從 2025 年的 80.2 億美元成長到 2034 年的 189.3 億美元，2026 年至 2034 年的複合年成長率為 10.01%。

隨著個人化醫療在癌症治療中的重要性日益凸顯，腫瘤領域伴隨診斷檢測的全球市場正在迅速擴張。伴隨診斷檢測能夠幫助判斷患者是否可能從特定的癌症治療中獲益。這些檢測透過分析腫瘤的​​基因突變、生物標記和其他分子特徵，為治療決策提供支持。

全球癌症發生率的上升和標靶治療的日益普及是推動市場成長的主要因素。製藥公司和診斷設備製造商正攜手合作，在研發新藥的同時開發伴隨診斷測試。分子診斷和基因測序技術的進步也提高了這些測試的準確性和可靠性。

未來，隨著精準癌症治療的進步，市場預計將顯著成長。隨著癌症基因組研究和生物標記發現研究的活性化，新型診斷工具的開發也將持續推進。隨著醫療機構致力於提供個人化癌症治療，伴隨診斷測試將在改善治療效果方面發揮至關重要的作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球腫瘤伴隨診斷檢驗市場：依檢測技術分類

  • 市場分析、洞察與預測
  • 蛋白質檢測
  • DNA檢測
  • 其他

第5章 全球腫瘤領域伴隨診斷檢驗市場：依生物標記分類

  • 市場分析、洞察與預測
  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • 其他

第6章 全球腫瘤伴隨診斷測試市場：依癌症類型分類

  • 市場分析、洞察與預測
  • 乳癌
  • 肺癌
  • 結腸癌
  • 肝癌
  • 黑色素瘤
  • 其他

第7章 全球腫瘤領域伴隨診斷測試市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 診斷檢查室
  • 其他

第8章 全球腫瘤伴隨診斷測試市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Genomic Health Inc
    • Qiagen NV
    • Agilent Technologies Inc
    • Agendia NV
    • BioMAfA（C）Rieux SA
    • Illumina Inc
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc
    • BioGenex Laboratories Inc
簡介目錄
Product Code: VMR112114403

The Companion Diagnostic Tests in Oncology Market size is expected to reach USD 18.93 Billion in 2034 from USD 8.02 Billion (2025) growing at a CAGR of 10.01% during 2026-2034.

The global companion diagnostic tests in oncology market is expanding rapidly as personalized medicine becomes more important in cancer treatment. Companion diagnostics are tests that help determine whether a patient is likely to benefit from a specific cancer therapy. These tests analyze genetic mutations, biomarkers, or other molecular characteristics of tumors to guide treatment decisions.

The increasing prevalence of cancer worldwide and the growing adoption of targeted therapies are major drivers of market growth. Pharmaceutical companies and diagnostic manufacturers are collaborating to develop companion diagnostic tests alongside new cancer drugs. Advances in molecular diagnostics and genomic sequencing technologies are also improving the accuracy and reliability of these tests.

Looking ahead, the market is expected to grow significantly as precision oncology continues to evolve. Increasing research in cancer genomics and biomarker discovery will lead to the development of new diagnostic tools. As healthcare providers focus on delivering personalized cancer treatments, companion diagnostic testing will play an essential role in improving treatment outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Detection Technique

  • Protein Detection
  • DNA Detection
  • Others

By Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Diagnostic Labs
  • Others

COMPANIES PROFILED

  • Abbott Laboratories, F HoffmannLa Roche Ltd, Genomic Health Inc, Qiagen NV, Agilent Technologies Inc, Agendia NV, bioMrieux SA, Illumina Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, BioGenex Laboratories Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Detection Technique
  • 4.2. Protein Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. DNA Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY BIOMARKER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Biomarker
  • 5.2. EGFR Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. KRAS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. HER2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. BRAF V600E Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Cancer Type
  • 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY END-USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-user
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Detection Technique
    • 8.2.2 By Biomarker
    • 8.2.3 By Cancer Type
    • 8.2.4 By End-user
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Detection Technique
    • 8.3.2 By Biomarker
    • 8.3.3 By Cancer Type
    • 8.3.4 By End-user
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Detection Technique
    • 8.4.2 By Biomarker
    • 8.4.3 By Cancer Type
    • 8.4.4 By End-user
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Detection Technique
    • 8.5.2 By Biomarker
    • 8.5.3 By Cancer Type
    • 8.5.4 By End-user
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Detection Technique
    • 8.6.2 By Biomarker
    • 8.6.3 By Cancer Type
    • 8.6.4 By End-user
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Abbott Laboratories
    • 10.2.2 F. Hoffmann-La Roche Ltd
    • 10.2.3 Genomic Health Inc
    • 10.2.4 Qiagen N.V
    • 10.2.5 Agilent Technologies Inc
    • 10.2.6 Agendia N.V
    • 10.2.7 BioMAfA(C)Rieux SA
    • 10.2.8 Illumina Inc
    • 10.2.9 Siemens Healthineers AG
    • 10.2.10 Thermo Fisher Scientific Inc
    • 10.2.11 BioGenex Laboratories Inc